Abstract: A system comprises a validation module and an analysis module. The validation module is configured to receive input data from an electronic device operated by a test-taker during a biopsychosocial assessment. The input data includes a plurality of input terms that describes a functioning of the test-taker. The validation module is configured to validate the plurality of input terms based on a plurality of pre-defined terms stored within the system. The analysis module is configured to generate a list of potential biopsychosocial-related issues associated with the test-taker based on the validated input terms, and to generate a recommendation of one or more tests to administer to the test-taker based on this list. The analysis module is further configured to transmit an output signal representing the recommendation to an electronic device such that the one or more recommended tests are presented at an electronic device.

Abstract: Methods of reducing the number of platelets in mammals and preventing or treating pro-thrombotic conditions and diseases that are characterized by an excess of, or undesired activation of, platelets using inhibitors of anti-apoptotic Bcl-2 family protein members is disclosed.

Abstract: Methods of reducing the number of platelets in mammals and preventing or treating pro-thrombotic conditions and diseases that are characterized by an excess of, or undesired activation of, platelets using inhibitors of anti-apoptotic Bcl-2 family protein members is disclosed.

Abstract: The invention relates to pharmaceutical compositions comprising combinations of ABT-751 and anti-cancer drugs. These combinations have additive antitumorigenesis activity. This invention also relates to methods of treatment using the combinations.

Abstract: The invention relates to pharmaceutical compositions comprising combinations of ABT-751 and anti-cancer drugs. These combinations have additive antitumorigenesis activity. This invention also relates to methods of treatment using the combinations.

Abstract: Compositions comprising a cancer drug, a continuous oral dosing schedule with a drug which binds to the colchicine site of tubulin ?-subunits, and methods of treating cancer in a pediatric patient using continuous dosing schedules are disclosed.

Abstract: Compositions comprising one or more cancer drugs, continuous oral dosing schedule with drugs which bind to the colchicine site of tubulin ?-subunits, and methods of treating diseases using continuous dosing schedules are disclosed.

Abstract: Compounds having formula (I) inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

Abstract: Compounds having formula (I) inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

Abstract: The subject invention relates to a novel small molecule, referred to as alpha-(trichloromethyl)-4-Pyridineethanol (PETCM), as well as to uses thereof. PETCM was identified and isolated by high throughput screening and is an activator of caspase-3. Using PETCM in combination with biochemical fractionation, a novel pathway that regulates mitochondria-initiated caspase activation was also identified. This pathway comprises tumor suppressor PHAP proteins and oncoprotein prothymosin-alpha. PETCM relieves prothymosin-alpha inhibition and allows apoptosome to form at a physiological concentration of dATP.

Abstract: Compositions comprising one or more cancer drugs, continuous oral dosing schedule with drugs which bind to the colchicine site of tubulin ?-subunits, and methods of treating diseases using continuous dosing schedules are disclosed.

Abstract: Compounds having formula (I) 1

Abstract: Compounds having formula (I) inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.